KR20090010030A - Vegf 수용체 융합 단백질 및 그의 용도 - Google Patents

Vegf 수용체 융합 단백질 및 그의 용도 Download PDF

Info

Publication number
KR20090010030A
KR20090010030A KR1020087025464A KR20087025464A KR20090010030A KR 20090010030 A KR20090010030 A KR 20090010030A KR 1020087025464 A KR1020087025464 A KR 1020087025464A KR 20087025464 A KR20087025464 A KR 20087025464A KR 20090010030 A KR20090010030 A KR 20090010030A
Authority
KR
South Korea
Prior art keywords
angiogenesis
fusion protein
thr
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020087025464A
Other languages
English (en)
Korean (ko)
Inventor
데차오 미카엘 유
Original Assignee
쳉두 캉홍 바이오테크놀로지스 코. 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 filed Critical 쳉두 캉홍 바이오테크놀로지스 코. 리미티드
Publication of KR20090010030A publication Critical patent/KR20090010030A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020087025464A 2006-03-31 2007-03-29 Vegf 수용체 융합 단백질 및 그의 용도 Withdrawn KR20090010030A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200610066257.2 2006-03-31
CNB2006100662572A CN100502945C (zh) 2006-03-31 2006-03-31 Vegf受体融合蛋白在治疗眼睛疾病中的应用

Publications (1)

Publication Number Publication Date
KR20090010030A true KR20090010030A (ko) 2009-01-28

Family

ID=37736587

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087025464A Withdrawn KR20090010030A (ko) 2006-03-31 2007-03-29 Vegf 수용체 융합 단백질 및 그의 용도

Country Status (10)

Country Link
US (1) US20090264358A1 (cg-RX-API-DMAC7.html)
EP (1) EP2000483A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009531036A (cg-RX-API-DMAC7.html)
KR (1) KR20090010030A (cg-RX-API-DMAC7.html)
CN (1) CN100502945C (cg-RX-API-DMAC7.html)
AU (1) AU2007234272A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0710223A2 (cg-RX-API-DMAC7.html)
CA (1) CA2647142A1 (cg-RX-API-DMAC7.html)
RU (1) RU2008136655A (cg-RX-API-DMAC7.html)
WO (1) WO2007112675A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3142945A1 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
CN101279092B (zh) * 2007-04-02 2010-10-27 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗与血管生成有关的疾病中的应用
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
KR101248912B1 (ko) * 2009-12-31 2013-03-29 한양대학교 산학협력단 항혈관신생 활성을 가지는 재조합 아데노바이러스
CN102233132B (zh) * 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN103816115B (zh) * 2010-08-31 2017-06-27 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
CN102380096B (zh) * 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
JP6631865B2 (ja) * 2014-08-11 2020-01-15 日本化薬株式会社 TGFβ阻害機能を持つキメラタンパク質
CN106999511A (zh) 2014-12-11 2017-08-01 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
KR20200093621A (ko) 2017-11-30 2020-08-05 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
BR112021003275A2 (pt) 2018-12-07 2021-06-22 Remegen Co., Ltd. inibidor de angiogênese bifuncional e uso do mesmo
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CN115335529B (zh) * 2019-11-26 2026-07-03 马萨诸塞大学 用于递送kh902(康柏西普)的重组腺相关病毒及其用途
IL309560B2 (en) 2019-12-06 2025-05-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
FI4185318T3 (fi) 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
TW202400214A (zh) 2022-03-15 2024-01-01 美商再生元醫藥公司 用於血管新生眼睛病症之治療之延長高劑量vegf拮抗劑方案
US20230295266A1 (en) 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
EP4588469A4 (en) 2022-09-16 2026-03-04 Qilu Pharmaceutical Co Ltd STABLE, HIGH-CONCENTRATION, SPONTANEOUSLY BUFFERING PHARMACEUTICAL COMPOSITION
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121712520A (zh) 2023-06-23 2026-03-20 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
CN120204358A (zh) * 2023-12-27 2025-06-27 成都康弘生物科技有限公司 一种含有抗vegf的融合蛋白的药物组合物
WO2025217334A1 (en) 2024-04-09 2025-10-16 Regeneron Pharmaceuticals, Inc. Low concentration vegf receptor fusion protein containing formulations
CN118108862B (zh) * 2024-04-29 2024-08-09 上海鼎新基因科技有限公司 抗血管新生的融合蛋白及其应用
KR20260096819A (ko) 2024-12-13 2026-06-24 리제너론 파아마슈티컬스, 인크. 망막 정맥 폐쇄에 속발하는 혈관신생 눈 장애의 치료를 위한 연장된 고용량 vegf 길항제 레지먼
WO2026148214A1 (en) 2025-01-02 2026-07-09 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing buffer free formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101433715B (zh) * 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AU2004273619A1 (en) * 2003-09-23 2005-03-31 Novartis Ag Combinations of a VEGF receptor inhibitor with other therapeutic agents
CN1304427C (zh) * 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
ES2381014T3 (es) * 2004-06-08 2012-05-22 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína quimérica inhibidora de la angiogénesis y el uso

Also Published As

Publication number Publication date
AU2007234272A1 (en) 2007-10-11
WO2007112675A8 (fr) 2009-07-09
EP2000483A4 (en) 2009-10-28
CN1915427A (zh) 2007-02-21
EP2000483A9 (en) 2009-03-18
JP2009531036A (ja) 2009-09-03
US20090264358A1 (en) 2009-10-22
RU2008136655A (ru) 2010-05-10
CN100502945C (zh) 2009-06-24
CA2647142A1 (en) 2007-10-11
EP2000483A2 (en) 2008-12-10
WO2007112675A1 (fr) 2007-10-11
BRPI0710223A2 (pt) 2011-08-02

Similar Documents

Publication Publication Date Title
EP2000483A2 (en) Vegf receptor fusion protein and use thereof
AU2024204677A1 (en) Use of a VEGF antagonist to treat angiogenic eye disorders
US7306799B2 (en) Use of VEGF inhibitors for treatment of eye disorders
KR102819739B1 (ko) 유전적 작제물
EA007967B1 (ru) Защита, восстановление и усиление эритропоэтинреактивных клеток, тканей и органов
US20250064977A1 (en) Nucleic Acid-Based Compositions and Methods for Treating Small Vessel Diseases
JPH07507055A (ja) 眼の創傷の治癒における血小板誘導化成長因子の使用
US20100129435A1 (en) Methods and compositions for treatment of ocular neovascularization and neural injury
JP5208135B2 (ja) 組換え白血球阻害因子とヒルゲンのキメラタンパク質及びその薬物組成物
US20210393738A1 (en) Method For Treating Angiogenic Eye Disorders Using Vegf Antagonists
CN100567325C (zh) Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
JP2020523307A (ja) 血管新生緑内障を治療するための非抗体vegfアンタゴニスト
US6025329A (en) Method for treating ophthalmic diseases
JP5272228B2 (ja) 可溶性トロンボモジュリン変異体を用いる急性腎不全の治療
US20240299564A1 (en) Peptide carriers and delivery to the eye of a subject
CN107050429A (zh) 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用
EP4429693B1 (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
US9266933B2 (en) Polypeptides inhibiting neovascularization and uses thereof
CN109475598A (zh) 眼部疾病的治疗
HK40115628B (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
HK40115628A (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
US8933031B2 (en) Polypeptide inhibiting angiogenesis and application thereof
CN120676931A (zh) Engrailed蛋白的稳定水性组合物
HK40042305A (en) Bifunctional angiogenesis inhibitor and use thereof
HK40052983B (zh) 含有高浓度vegf受体融合蛋白的制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000